In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Genmab ADR’s stock clocked out at $23.82, up 1.71% from its previous closing price of $23.42. In other words, the price has increased by $1.71 from its previous closing price. On the day, 1.0 million shares were traded. GMAB stock price reached its highest trading level at $23.93 during the session, while it also had its lowest trading level at $23.63.
Ratios:
To gain a deeper understanding of GMAB’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.05 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.58. For the most recent quarter (mrq), Quick Ratio is recorded 6.20 and its Current Ratio is at 6.22. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Leerink Partners Upgraded its Market Perform to Outperform on February 13, 2025, while the target price for the stock was maintained at $27.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 17 ’25 when Klimovsky Judith V bought 1,300 shares for $51.69 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMAB now has a Market Capitalization of 14650990592 and an Enterprise Value of -1310610816. As of this moment, Genmab’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.89, and their Forward P/E ratio for the next fiscal year is 12.56. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.03. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.32 while its Price-to-Book (P/B) ratio in mrq is 2.76. Its current Enterprise Value per Revenue stands at -0.359 whereas that against EBITDA is -0.987.
Stock Price History:
The Beta on a monthly basis for GMAB is 0.93, which has changed by -0.13350308 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, GMAB has reached a high of $27.94, while it has fallen to a 52-week low of $17.24. The 50-Day Moving Average of the stock is 8.75%, while the 200-Day Moving Average is calculated to be 12.92%.
Shares Statistics:
It appears that GMAB traded 1.30M shares on average per day over the past three months and 1351290 shares per day over the past ten days. A total of 615.07M shares are outstanding, with a floating share count of 615.07M. Insiders hold about 0.00% of the company’s shares, while institutions hold 10.46% stake in the company. Shares short for GMAB as of 1753920000 were 3588106 with a Short Ratio of 2.77, compared to 1751241600 on 1745895. Therefore, it implies a Short% of Shares Outstanding of 3588106 and a Short% of Float of 0.58999998.
Earnings Estimates
A detailed examination of Genmab ADR (GMAB) is currently in progress, with 3.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.37, with high estimates of $0.53 and low estimates of $0.15.
Analysts are recommending an EPS of between $1.79 and $1.69 for the fiscal current year, implying an average EPS of $1.73. EPS for the following year is $1.64, with 4.0 analysts recommending between $1.99 and $1.38.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $6.21B. It ranges from a high estimate of $6.51B to a low estimate of $5.95B. As of the current estimate, Genmab ADR’s year-ago sales were $5.54BFor the next quarter, 9 analysts are estimating revenue of $6.47B. There is a high estimate of $6.88B for the next quarter, whereas the lowest estimate is $6.09B.
A total of 19 analysts have provided revenue estimates for GMAB’s current fiscal year. The highest revenue estimate was $25.25B, while the lowest revenue estimate was $21.74B, resulting in an average revenue estimate of $23.27B. In the same quarter a year ago, actual revenue was $21.53BBased on 19 analysts’ estimates, the company’s revenue will be $26.81B in the next fiscal year. The high estimate is $29.33B and the low estimate is $23.32B.
